Top Ten most popular articles on Pharmafile.com this week

pharmafile | November 15, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

As we close in on the weekend, it’s been a week characterised by data reveals and crucial marketing approvals, including the big news that the deal struck between NHS England and Vertex to provide access to its cystic fibrosis portfolio for English patients has now been adopted in Northern Ireland and Wales. Meanwhile, the same week saw the ground-breaking news that the NHS will utilise its first cannabis-based therapies after NICE decided to approve two GW Pharma therapies.

10. Novartis’ Kisqali approved for NHS Scotland in most common advanced breast cancer

NHS patients in Scotland will soon be able to access Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) after the SMC moved to authorise the drug in combination with fulvestrant for routine use on the health service in the treatment of metastatic HR+/HER2- breast cancer – the most common advanced form of the disease.    

9. MSD secures EU approval for its Zaire Ebola vaccine Ervebo

MSD has scored approval from the European Commission for Ervebo, the company’s Zaire Ebola vaccine, for the prevention of Ebola virus disease (EVD) in patients at least 18 years old, it has emerged.             

8. Vertex’s cystic fibrosis portfolio to be made available across Northern Ireland and Wales

After drawn out negotiations and much discontent among cystic fibrosis (CF) patients and their advocates, Vertex has announced that a deal has finally been reached that will make its crucial CF medications available to patients across Wales and Northern Ireland.

7. AnaptysBio’s etokimab fails in moderate-to-severe atopic dermatitis

AnaptysBio has announced disappointing new Phase 2b data for its anti-IL-33 candidate etokimab in the treatment of moderate-to-severe atopic dermatitis.

6. Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line maintenance treatment of multiple myeloma in adult patients not treated with stem cell transplantation.

5. Novartis reveals strong Phase 2b data for tropifexor in non-alcoholic steatohepatitis

The latest findings have been revealed from the final stage of Novartis’ Phase 2b evaluation of its non-bile acid FXR agonist tropifexor in the treatment of biopsy-confirmed stage 2-3 fibrotic non-alcoholic steatohepatitis (NASH).

4. NHS to utilise first-ever cannabis-based therapies following NICE recommendation of two GW Pharma drugs

The NHS is authorised to use its first two cannabis-based medicines for routine use after NICE saw fit to recommend both Epidyolex (cannabidiol) oral solution and Sativex (nabiximols) from the UK’s own GW Pharmaceuticals.

3. AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials

AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) levels in non-dialysis-dependent (NDD) and dialysis-dependent (DD) patients with anaemia as a result of chronic kidney disease after meeting its primary endpoint in two separate clinical trials.

2. Roche terminates Duchenne muscular dystrophy candidate due to poor clinical outlook

Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent that the candidate would not come to show clinical benefit in the treatment of Duchenne muscular dystrophy (DMD).

1. Roche’s risdiplam hits main goal in spinal muscular atrophy type 2 or 3

Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam met its primary endpoint in the treatment of type 2 or 3 spinal muscular atrophy (SMA) in patients between the age of 2 and 25.

Related Content

No items found

Latest content